Keyword: Allergan

Last week, Allergan's CEO told investors that Botox “continues to remain very strong” in migraine despite the arrival of three new CGRP drugs. But how strong?

After controversy and a price-hiking pause for some companies last year, several drugmakers are raising prices in early 2019.

Merz Americas hopes to grab cosmetic injection share with two new ad campaigns that push awareness of options other than market leader Botox.

J&J CEO Alex Gorsky said Amazon could offer expertise in distribution as well as shake up reimbursement in a potential pharma entry.

A judge ruled that Teva must face a lawsuit alleging employment discrimination in September, and now jurors ordered the company to pay $6.3 million.

Philadelphia's city council is considering legislation to regulate pharma reps including prohibiting any gifts to healthcare providers and staff.

Too-snug jeans in the back of the closet? Allergan’s newest spokescelebrity can relate, and she's talking about her CoolSculpting story.

A top pharma CEO says President Trump is right to say other countries benefit from higher U.S. drug prices, but he’s not sold on proposals for a fix.

With generics expected soon for eye drug Restasis, Allergan has canceled a $200 million expansion at its Waco, Texas, manufacturing plant.

Growth for Allergan and Ironwood’s Linzess is easing up, and one analyst thinks Allergan may not be part of the solution.